The breakthrough therapy designation for the Keytruda, Lenvima combo is for the first-line treatment of patients with advanced unresectable HCC that is not responsive to locoregional treatment. Keytruda
The company said that the week 96 data from the two-cohort BRIGHTE trial revealed that fostemsavir continued to improve virologic suppression and immunologic response. Fostemsavir is a prodrug
A total of 396 patients with moderate-to-severe psychotic symptoms were randomized to receive either pimavanserin or placebo added to their current antipsychotic treatment. There is currently no FDA-approved
Pregabalin Capsules had U.S. sales of approximately $5,497 million for the 12 months ending March 2019, according to IMS Health. Pregabalin Capsules are indicated for management of neuropathic
In this regard, the company has submitted an extension application to the European Medicines Agency (EMA) for the subcutaneous use of daratumumab, co-formulated with recombinant human hyaluronidase PH20
AHF’s demand for a victim compensation fund from Gilead comes as HIV Litigation Attorneys announce its filing last Friday in Alameda County (Superior Court of California County of
As per the agreement terms, Astellas will undertake the development and commercialisation of FX-322 outside of the US, while Frequency will be responsible for the development and commercialisation
The new site builds on Kite’s existing state-of-the-art manufacturing capabilities to deliver innovative cell therapies for people with cancer, including Yescarta (axicabtagene ciloleucel), Kite’s first commercially available chimeric
STING pathway signaling plays an important role in the generation of an immune response directed at tumors, and enhancing STING signaling has shown promise in a variety of
In January 2018, the company announced that crizanlizumab was granted breakthrough therapy designation by the FDA. Novartis’ application for the investigational drug is backed by results from a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.